ADMA Biologics, Inc.
ADMANASDAQHealthcare● Active
$8.06
+$0.09(+1.13%)
Market Cap$1.9B
P/E Ratio—
52W High$22.37
52W Low$7.21
ADMA Biologics, Inc. (ADMA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADMA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.51B | $0.43B | $0.26B | $0.15B | $0.08B |
| Cost of Revenue | $0.22B | $0.21B | $0.17B | $0.12B | $0.08B |
| Gross Profit | $0.29B | $0.22B | $0.09B | $0.04B | $0.00B |
| Gross Margin %(computed) | 57.39% | 51.48% | 34.44% | 22.89% | 1.45% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.10B | $0.08B | $0.07B | $0.07B | $0.06B |
| Operating Income | $0.19B | $0.14B | $0.02B | ($0.04B) | ($0.06B) |
| Operating Margin %(computed) | 37.53% | 32.59% | 8.38% | -25.55% | -72.12% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.03B | $0.02B | $0.01B |
| Income Before Tax | $0.18B | $0.13B | ($0.03B) | ($0.07B) | ($0.07B) |
| Income Tax Expense | $0.04B | ($0.07B) | $0.00B | $0.00B | $0.00B |
| Net Income | $0.15B | $0.20B | ($0.03B) | ($0.07B) | ($0.07B) |
| Net Margin %(computed) | 28.80% | 46.35% | -10.94% | -42.77% | -88.52% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.62 | $0.85 | $-0.13 | $-0.43 | $-0.61 |
| Wtd Avg Shares | 0.24B | 0.23B | 0.22B | 0.20B | 0.14B |
| EBITDA | $0.20B | $0.15B | $0.01B | ($0.04B) | ($0.05B) |
| EBITDA Margin %(computed) | 38.78% | 34.63% | 1.98% | -25.64% | -65.60% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more ADMA Biologics, Inc. data
About ADMA Biologics, Inc. (ADMA) Income Statement
ADMA Biologics, Inc. (ADMA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ADMA reported revenue of $0.51B, gross profit of $0.29B (gross margin 57.39%), and net income of $0.15B — a net profit margin of 28.80%.
Frequently asked questions
ADMA · 4 questionsADMA Biologics, Inc. (ADMA) reported revenue of $0.51B for 2025, up 19.6% year-over-year.
ADMA revenueADMA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08